News

Biomanufacturing the Next Generation of Cancer-Killing Immune Cells

By: 

Audrey Grayson
Irfan Bandey
Irfan Bandey

Navin Varadarajan receives National Science Foundation award to boost effectiveness of immunotherapy

Back in the days when all medicines were made out of chemicals found in nature, manufacturing drugs was somewhat of a breeze.

Take aspirin, for example. The chemical makeup of aspirin is simple; When you look at the drug under a microscope its molecules will all look exactly the same. Aspirin is as easy to characterize as it is to manufacture.

But a newer class of drugs known as biopharmaceuticals, which are drugs derived from living systems such as proteins, are much more difficult to characterize and manufacture.

Living cells – like living people – undergo constant changes. How do you classify a living organism? How do you describe a system that is constantly in flux? And, more confounding, how do you reliably manufacture identical living systems the same way each time, billions of times over?

The answers to those questions are at the crux of an emerging field of cancer treatment called immunotherapy, which harnesses the body’s own immune cells (called T cells) to recognize and kill cancer cells. It’s a promising field, but only remains effective in about 20 percent of cancer patients.

Navin Varadarajan, associate professor of chemical and biomolecular engineering at the Cullen College, received more than $500,000 from the National Science Foundation (NSF) to boost the biomanufacturing of T cells for immunotherapy by identifying the key qualities that allow certain immune cells to become cancer killers.

Engineering cancer killers

Immunotherapy works by engineering immune cells to seek out, recognize and attack cancer cells inside the body. T cells, like any living organism, require nutrients to survive, but tumors are very low-nutrient environments. Varadarajan’s task is to design immune system cells that can survive without life-sustaining nutrients long enough to kill off the tumor cells.

“If the T cells are not able to survive inside of the tumor without nutrients then they won’t be able to fight off the cancer cells,” Varadarajan said. “We want to know what allows certain immune cells to survive and not others.”

Working with postdoctoral researcher Irfan Bandey and MD Anderson collaborator Michael Rytting, Varadarajan will profile immune cells using his novel research platform called TIMING, which allows the team to study single-cell interactions between T cells and tumor cells. The immune cells will then be infused into mice models of leukemia; Whichever T cells persist and succeed in killing their opponents will be characterized once more using the single-cell assay.

“We need to create a map connecting the metabolism of the T cell to its ability to fight off the tumor cell successfully in order to say, ‘These are the characteristics in the cells that we need in order to fight off the tumor cells,’” said Varadarajan.

Ultimately, Varadarajan hopes to give oncologists the ability to predict how effective immune cells will be at killing a cancer before a leukemia patient receives a transfusion of T cells.

But first things first: “You have to know what you want before you figure out how to make a billion copies of it,” he said.

Faculty: 

Department/Academic Programs: 

Related News Stories

University of Houston Partners with AuraVax Therapeutics on COVID-19 Vaccine

Navin Varadarajan, M.D. Anderson Professor of Chemical and Biomolecular Engineering, has created a nasal vaccine for COVID-19 and a company to market it in partnership with the University of Houston.

The University of Houston has entered into an exclusive license option agreement with AuraVax Therapeutics Inc., a Houston, TX based biotech company developing novel vaccines to help patients defeat debilitating respiratory diseases such as COVID-19. Under terms of the agreement, AuraVax has the option to exclusively license a new intranasal COVID-19 vaccine technology developed by Dr. Navin Varadarajan, M.D. Anderson Professor of Chemical and Biomolecular Engineering.

Faster swimming bacteria could help with spills

Narendra Dewangan, a graduate student of Dr. Jacinta Conrad, has completed work with the Conrad Research Group on how faster swimming bacteria could be used to help with removal of pollutants.

A new paper and research from the Conrad Research Group of the Department of Chemical and Biomolecular Engineering at the University of Houston’s Cullen College of Engineering looks at how bacteria could be used to help with removal of pollutants, like in oil spills and wastewater treatment.

Rapid tests for COVID-19 now, other diseases later the goal for Kourentzi

Dr. Katerina Kourentzi, Research Associate Professor of Chemical and Biomolecular Engineering, is developing a saliva-based lateral flow assay rapid test for COVID-19 detection. The test strips for the assay are designed using the Biodot XYZ3060 Dispensing Platform.

The development of point-of-care tests – and as of late, for COVID-19 – has been the primary focus of Dr. Katerina Kourentzi, Research Associate Professor of Chemical and Biomolecular Engineering in the William A. Brookshire Department of Chemical and Biomolecular Engineering at the University of Houston's Cullen College of Engineering.